130 related articles for article (PubMed ID: 30372726)
21. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B
Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967
[TBL] [Abstract][Full Text] [Related]
22. First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
Schneeweiss A; Förster F; Tesch H; Aktas B; Gluz O; Geberth M; Hertz-Eichenrode MM; Schönegg W; Schumacher C; Kutscheidt A; Kiewitz C; Klawitter S; Schmidt M
Anticancer Res; 2016 Mar; 36(3):967-74. PubMed ID: 26976985
[TBL] [Abstract][Full Text] [Related]
23. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
24. The role of angiogenesis inhibition in the treatment of breast cancer.
Sledge GW; Rugo HS; Burstein HJ
Clin Adv Hematol Oncol; 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2. PubMed ID: 17139244
[TBL] [Abstract][Full Text] [Related]
25. Multiple cutaneous acral metastases in a woman with breast adenocarcinoma treated with pegylated liposomal doxorubicin: incidental or aetiological association?
Karamouzis MV; Ardavanis A; Alexopoulos A; Papadopoulou A; Apostolikas N; Rigatos G
Eur J Cancer Care (Engl); 2005 Jul; 14(3):267-71. PubMed ID: 15952972
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins.
Cohen AD; Mermershtain W; Geffen DB; Schoenfeld N; Mamet R; Cagnano E; Cohen Y; Halevy S
J Dermatolog Treat; 2005 Feb; 16(1):19-21. PubMed ID: 15897162
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H
Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074
[TBL] [Abstract][Full Text] [Related]
28. [Usefulness of bevacizumab combination chemotherapy for advanced breast cancer].
Aomatsu N; Kashiwagi S; Morisaki T; Ishihara S; Asano Y; Watanabe M; Noda S; Kawajiri H; Takashima T; Onoda N; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2393-5. PubMed ID: 24394123
[TBL] [Abstract][Full Text] [Related]
29. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
Coltelli L; Allegrini G; Orlandi P; Giuntini N; Alì G; Fioravanti A; Bona E; Barletta MT; Fontanini G; Del Tacca M; Danesi R; Falcone A; Bocci G
Pharmacogenomics; 2009 Aug; 10(8):1225-9. PubMed ID: 19663667
[TBL] [Abstract][Full Text] [Related]
30. [A Case of Chemotherapy with Low-Dose Paclitaxel and Bevacizumab for Elderly Recurrent Breast Cancer Patient].
Munemoto M; Kano S; Ishikawa S; Makita N; Yagi Y; Oonishi I; Kayahara M
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2038-2040. PubMed ID: 33468793
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].
Suzuki S; Sakurai K; Nagashima S; Hara Y; Amano S; Enomoto K; Makishima M
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1289-91. PubMed ID: 25335720
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.
Ray-Coquard IL; Domont J; Tresch-Bruneel E; Bompas E; Cassier PA; Mir O; Piperno-Neumann S; Italiano A; Chevreau C; Cupissol D; Bertucci F; Bay JO; Collard O; Saada-Bouzid E; Isambert N; Delcambre C; Clisant S; Le Cesne A; Blay JY; Penel N
J Clin Oncol; 2015 Sep; 33(25):2797-802. PubMed ID: 26215950
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
Zhai X; Hong R; Fan Y; Yuan P; Wang J; Sang D; Chen J; Zhao C; Ou K; Ma F; Xu B
Thorac Cancer; 2018 May; 9(5):613-620. PubMed ID: 29575760
[TBL] [Abstract][Full Text] [Related]
34. [A case of stage IV breast cancer with long-term partial response treated with tri-weekly paclitaxel plus bevacizumab].
Okamoto A; Nakatsukasa K; Fujita Y; Sugimoto R; Sakaguchi K; Taguchi T
Gan To Kagaku Ryoho; 2015 Mar; 42(3):343-6. PubMed ID: 25812504
[TBL] [Abstract][Full Text] [Related]
35. The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion.
Wang Z; Zheng Y; Fang Z
Rev Assoc Med Bras (1992); 2018 Mar; 64(3):230-233. PubMed ID: 29641777
[TBL] [Abstract][Full Text] [Related]
36. [Combination Therapy of Bevacizumab plus Paclitaxel Was Effective for a Metastatic Choroidal Tumor Secondary to Breast Cancer in a Patient with Ocular Symptoms].
Hattori M; Shirahane K; Sakai M; Sassa Y; Nishihara Y; Aibe H; Masuda M; Mori D
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1221-1224. PubMed ID: 32829359
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer.
Yoshinami T; Yagi T; Okuno J; Kittaka N; Ishitobi M; Sugimoto N; Nakayama T; Tamaki Y; Imamura F
Breast Cancer; 2017 Jan; 24(1):147-151. PubMed ID: 27010394
[TBL] [Abstract][Full Text] [Related]
40. [A case of bone marrow carcinomatosis with disseminated intravascular coagulation arising from breast cancer successfully treated with paclitaxel plus bevacizumab].
Kawai H; Sugimoto R; Miyauchi S; Yoshida R; Waki N; Hirayama S; Ishizaki M; Nishi H; Yamashita K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1957-9. PubMed ID: 25731388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
